微小RNA在胰腺腺癌诊断与治疗中的作用
The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma.
作者信息
Diab Maria, Muqbil Irfana, Mohammad Ramzi M, Azmi Asfar S, Philip Philip A
机构信息
Department of Internal Medicine, School of Medicine, Wayne State University, Detroit, MI 48201, USA.
Department of Oncology, Karmanos Cancer institute, Wayne State University, Detroit, MI 48201, USA.
出版信息
J Clin Med. 2016 Jun 16;5(6):59. doi: 10.3390/jcm5060059.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains a very challenging malignancy. Disease is diagnosed in an advanced stage in the vast majority of patients, and PDAC cells are often resistant to conventional cytotoxic drugs. Targeted therapies have made no progress in the management of this disease, unlike other cancers. microRNAs (miRs) are small non-coding RNAs that regulate the expression of multitude number of genes by targeting their 3'-UTR mRNA region. Aberrant expression of miRNAs has been linked to the development of various malignancies, including PDAC. In PDAC, a series of miRs have been defined as holding promise for early diagnostics, as indicators of therapy resistance, and even as markers for therapeutic response in patients. In this mini-review, we present an update on the various different miRs that have been defined in PDAC biology.
摘要
胰腺导管腺癌（PDAC）仍然是一种极具挑战性的恶性肿瘤。绝大多数患者在疾病晚期才被诊断出来，而且PDAC细胞通常对传统细胞毒性药物具有抗性。与其他癌症不同，靶向治疗在这种疾病的治疗中没有取得进展。微小RNA（miRs）是一类小的非编码RNA，通过靶向基因的3'-UTR mRNA区域来调节众多基因的表达。miRNAs的异常表达与包括PDAC在内的各种恶性肿瘤的发生发展有关。在PDAC中，一系列miRs已被确定有望用于早期诊断、作为治疗抗性的指标，甚至作为患者治疗反应的标志物。在本综述中，我们介绍了在PDAC生物学中已被确定的各种不同miRs的最新情况。
相似文献
1
The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma.微小RNA在胰腺腺癌诊断与治疗中的作用
J Clin Med. 2016 Jun 16;5(6):59. doi: 10.3390/jcm5060059.
2
The role of miRNAs in the diagnosis, chemoresistance, and prognosis of pancreatic ductal adenocarcinoma.微小RNA在胰腺导管腺癌的诊断、化疗耐药及预后中的作用
Ther Clin Risk Manag. 2018 Jan 25;14:179-187. doi: 10.2147/TCRM.S154226. eCollection 2018.
3
miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma.miRNA 和胰腺导管腺癌中的基因表达。
Am J Pathol. 2019 Jan;189(1):58-70. doi: 10.1016/j.ajpath.2018.10.005.
4
5
Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application.非编码 RNA 在胰腺癌中的作用：临床应用的挑战与机遇。
Cell Oncol (Dordr). 2016 Aug;39(4):295-318. doi: 10.1007/s13402-016-0275-7. Epub 2016 Apr 8.
6
MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm.微小RNA作为胰腺导管腺癌及其前驱病变胰腺上皮内瘤变的诊断标志物。
Cancer Genet. 2013 Jun;206(6):217-21. doi: 10.1016/j.cancergen.2013.05.020. Epub 2013 Aug 9.
7
Nickel's Role in Pancreatic Ductal Adenocarcinoma: Potential Involvement of microRNAs.镍在胰腺导管腺癌中的作用：微小RNA的潜在参与
Toxics. 2022 Mar 21;10(3):148. doi: 10.3390/toxics10030148.
8
Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis.通过加权基因共表达网络分析鉴定胰腺导管腺癌的候选 miRNA 生物标志物
Cell Oncol (Dordr). 2017 Apr;40(2):181-192. doi: 10.1007/s13402-017-0315-y. Epub 2017 Feb 15.
9
Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).胰腺导管腺癌 (PDAC) 的治疗趋势。
Expert Opin Investig Drugs. 2019 Feb;28(2):161-177. doi: 10.1080/13543784.2019.1557145. Epub 2018 Dec 16.
10
Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.对微切割组织进行的全球 microRNA 表达谱分析鉴定出 miR-135b 是胰腺导管腺癌的一种新型生物标志物。
Int J Cancer. 2012 Jul 15;131(2):E86-95. doi: 10.1002/ijc.26466. Epub 2011 Nov 19.
引用本文的文献
1
Phenotypic heterogeneity and tumor immune microenvironment directed therapeutic strategies in pancreatic ductal adenocarcinoma.胰腺导管腺癌的表型异质性与肿瘤免疫微环境导向治疗策略
Front Immunol. 2025 Mar 31;16:1573522. doi: 10.3389/fimmu.2025.1573522. eCollection 2025.
2
Methylation of Tumor Suppressive miRNAs in Plasma from Patients With Pancreaticobiliary Diseases.胆胰疾病患者血浆中肿瘤抑制性微小RNA的甲基化
Cancer Diagn Progn. 2022 May 3;2(3):378-383. doi: 10.21873/cdp.10120. eCollection 2022 May-Jun.
3
Down-regulation of MiR-539 Indicates Poor Prognosis in Patients with Pancreatic Cancer.MiR-539表达下调提示胰腺癌患者预后不良。
Open Life Sci. 2019 Jan 4;13:497-503. doi: 10.1515/biol-2018-0059. eCollection 2018 Jan.
4
MicroRNA-769-5p Inhibits Pancreatic Ductal Adenocarcinoma Progression by Directly Targeting and Downregulating ETS Proto-Oncogene 1.微小RNA-769-5p通过直接靶向并下调ETS原癌基因1抑制胰腺导管腺癌进展。
Onco Targets Ther. 2019 Dec 31;12:11737-11750. doi: 10.2147/OTT.S218876. eCollection 2019.
5
The targeting of non‑coding RNAs by curcumin: Facts and hopes for cancer therapy (Review).姜黄素靶向非编码 RNA：癌症治疗的事实和希望（综述）。
Oncol Rep. 2019 Jul;42(1):20-34. doi: 10.3892/or.2019.7148. Epub 2019 May 3.
6
MicroRNA-634 functions as a tumor suppressor in pancreatic cancer via directly targeting heat shock-related 70-kDa protein 2.微小RNA-634通过直接靶向热休克相关70 kDa蛋白2在胰腺癌中发挥肿瘤抑制作用。
Exp Ther Med. 2019 May;17(5):3949-3956. doi: 10.3892/etm.2019.7433. Epub 2019 Mar 22.
7
MicroRNA‑3666 suppresses the growth and migration of glioblastoma cells by targeting KDM2A.MicroRNA-3666 通过靶向 KDM2A 抑制胶质母细胞瘤细胞的生长和迁移。
Mol Med Rep. 2019 Feb;19(2):1049-1055. doi: 10.3892/mmr.2018.9698. Epub 2018 Nov 27.
8
Clinical utilization of serum- or plasma-based miRNAs as early detection biomarkers for pancreatic cancer: A meta-analysis up to now.基于血清或血浆的微小RNA作为胰腺癌早期检测生物标志物的临床应用：截至目前的一项荟萃分析。
Medicine (Baltimore). 2018 Aug;97(35):e12132. doi: 10.1097/MD.0000000000012132.
9
Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Resection.术前血浆miR-21-5p是接受手术切除的胰腺导管腺癌患者的敏感生物标志物和独立预后因素。
Cancer Genomics Proteomics. 2018 Jul-Aug;15(4):321-327. doi: 10.21873/cgp.20090.
10
Nuclear Export Inhibition for Pancreatic Cancer Therapy.用于胰腺癌治疗的核输出抑制
Cancers (Basel). 2018 May 7;10(5):138. doi: 10.3390/cancers10050138.
本文引用的文献
1
MicroRNA-199a and -214 as potential therapeutic targets in pancreatic stellate cells in pancreatic tumor.微小RNA-199a和-214作为胰腺肿瘤中胰腺星状细胞的潜在治疗靶点。
Oncotarget. 2016 Mar 29;7(13):16396-408. doi: 10.18632/oncotarget.7651.
2
MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.微小RNA-323-3p通过直接抑制SMAD2和SMAD3抑制胰腺导管腺癌的细胞侵袭和转移。
Oncotarget. 2016 Mar 22;7(12):14912-24. doi: 10.18632/oncotarget.7482.
3
miR-137 Modulates a Tumor Suppressor Network-Inducing Senescence in Pancreatic Cancer Cells.miR-137调节一个诱导胰腺癌细胞衰老的肿瘤抑制网络。
Cell Rep. 2016 Mar 1;14(8):1966-78. doi: 10.1016/j.celrep.2016.01.068. Epub 2016 Feb 18.
4
Cancer statistics, 2016.癌症统计数据，2016 年。
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.
5
Contribution of microRNA analysis to characterisation of pancreatic lesions: a review.微小RNA分析对胰腺病变特征描述的贡献：综述
J Clin Pathol. 2015 Nov;68(11):859-69. doi: 10.1136/jclinpath-2015-203246. Epub 2015 Aug 27.
6
MicroRNA-200c overexpression inhibits chemoresistance, invasion and colony formation of human pancreatic cancer stem cells.微小RNA-200c过表达抑制人胰腺癌干细胞的化学抗性、侵袭和集落形成。
Int J Clin Exp Pathol. 2015 Jun 1;8(6):6533-9. eCollection 2015.
7
Circulating RNAs as new biomarkers for detecting pancreatic cancer.循环RNA作为检测胰腺癌的新型生物标志物
World J Gastroenterol. 2015 Jul 28;21(28):8527-40. doi: 10.3748/wjg.v21.i28.8527.
8
Circulating DNA and Micro-RNA in Patients with Pancreatic Cancer.胰腺癌患者的循环DNA和微小RNA
Pancreat Disord Ther. 2015 Jun;5(2). doi: 10.4172/2165-7092.1000156.
9
microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis.具有胰腺导管腺癌预后意义的 microRNAs：一项荟萃分析。
Eur J Cancer. 2015 Jul;51(11):1389-404. doi: 10.1016/j.ejca.2015.04.006. Epub 2015 May 19.
10
MicroRNA markers for the diagnosis of pancreatic and biliary-tract cancers.用于诊断胰腺癌和胆管癌的微小RNA标志物。
PLoS One. 2015 Feb 23;10(2):e0118220. doi: 10.1371/journal.pone.0118220. eCollection 2015.
Zotero 插件